login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Implantable cardioverter defibrillators in patients nearing the end of life


Monday, 23 Apr 2012 14:02
Rachel Lampert
Rachel Lampert


Rachel Lampert, associate professor of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, USA, is giving the talk “When to consider ICD deactivation: End-of-life issues” at Heart Rhythm 2012 (9–12 May 2012, Boston, USA). She talked to Cardiac Rhythm News about this topic.


When would you consider deactivating an implantable cardioverter defibrillator (ICD) in a patient who was nearing the end of their life?

The short answer is that ICD deactivation should be considered whenever a patient wants it to be considered. Even if a patient was not near the end of their life, legally and ethically, an ICD should be deactivated if the patient wants it to be deactivated.

However, the longer answer is that all patients with an ICD should have an opportunity to discuss the option of deactivation before they reach the end of their life (ie, shortly after implantation). The issue of deactivation should also be proactively discussed with a patient when their condition worsens and a good time to discuss the issue is when other preferences, such advanced directives [living wills] or a do not resuscitate (DNR) orders, are being discussed. It is not up to the physician when an ICD “should” be deactivated. The role of the physician is to make sure the patient understands the consequences of keeping it active versus deactivating it—when the patient has all of the available facts, then the decision to deactivate is up to them. The decision should be made in the context of the person’s overall goals for his or her care at that time.


What are the indications that a patient is nearing the end of their life?


Often it is not clear, and this is one of the difficult issues in discussing deactivation and one of the reasons it is so important to discuss the issue early on. Other times, though, physicians can tell as a patient’s disease course progresses (whether it is their underlying heart disease or another disease such as cancer) that the disease is overcoming the patient and therapeutic options are exhausted.


You state that a good time to discuss deactivation is when advance healthcare directives are being discussed. Would you therefore encourage patients to include their wishes on ICD deactivation in these documents and generally why in your view are such directives important?


I would definitely encourage patients to write an advanced directive, and that they include their wishes regarding ICD deactivation. This is important, as is all advanced planning relating to ICD deactivation at the end of life, to avoid potential shocks, which are painful, as a person is dying.


If a healthcare provider has ethical or moral concerns about deactivation, what should they do?


The American Medical Association (AMA) code of ethics states that a physician should not be compelled to perform an action that goes against his moral beliefs. However, our document (1) stresses that the healthcare provider should not attempt to impose his beliefs on the patient and should help direct the patient to an alternate provider who can help him.


References

1. Lampert et al. Heart Rhythm Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing the end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008–26




Add New Comment

Most popular


Medtronic launches Seeq wearable cardiac monitoring system in USA
Tuesday, 16 Sep 2014
Medtronic has announced the US launch of the Seeq Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose ... Medtronic launches Seeq wearable cardiac monitoring system in USA

Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results
Wednesday, 22 Oct 2014
An international multicentre registry evaluating the role of remote robotic navigation and contact force sensing in persistent atrial fibrillation (AF) treatment has found that, at one year, a higher ... Persistent atrial fibrillation treatment with robotic navigation and contact force sensing shows promising results

Preventice and eCardio merge as a new holding company
Friday, 12 Sep 2014
Preventice, developer of the PatientCare Platform and the BodyGuardian Remote Monitoring Sensor and eCardio, a provider of remote cardiac monitoring products and services, have announced a strategic ... Preventice and eCardio merge as a new holding company

Features


The importance of e-Health in daily cardiology practice
Monday, 15 Sep 2014
e-Health encompasses the use of information and communication technologies in support of health and health-related activities. Nico Bruining, Enrico G Caiani, Catherine E Chronaki, Przemyslaw Guzik ... The importance of e-Health in daily cardiology practice

Antithrombotic therapy after left atrial appendage closure
Wednesday, 10 Sep 2014
Uncertainty exists about the optimal post-interventional antithrombotic drug regimen as well as treatment duration after left atrial appendage closure; Boris Schmidt and KR Julian Chun review ... Antithrombotic therapy after left atrial appendage closure

Profiles


Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions